X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (113) 113
humans (111) 111
hematology (87) 87
female (73) 73
male (73) 73
middle aged (73) 73
aged (66) 66
life sciences (63) 63
adult (55) 55
oncology (52) 52
cancer (46) 46
transplantation (39) 39
treatment outcome (35) 35
[sdv.can]life sciences [q-bio]/cancer (34) 34
mantle cell lymphoma (32) 32
lymphomas (27) 27
retrospective studies (27) 27
antineoplastic combined chemotherapy protocols - therapeutic use (26) 26
chemotherapy (24) 24
rituximab (24) 24
survival (24) 24
[ sdv.can ] life sciences [q-bio]/cancer (23) 23
immunology (23) 23
lymphoma (23) 23
prognosis (23) 23
young adult (20) 20
adolescent (19) 19
aged, 80 and over (19) 19
survival analysis (19) 19
disease-free survival (18) 18
hemic and lymphatic diseases (18) 18
multiple myeloma (17) 17
analysis (15) 15
cell line, tumor (15) 15
recurrence (15) 15
stem cells (15) 15
therapy (15) 15
transplantation, homologous (15) 15
multiple-myeloma (14) 14
abridged index medicus (13) 13
bone-marrow-transplantation (13) 13
hematology, oncology and palliative medicine (13) 13
leukemia (13) 13
prospective studies (13) 13
survival rate (13) 13
trial (13) 13
apoptosis (12) 12
apoptosis - drug effects (12) 12
cyclophosphamide (12) 12
follow-up studies (12) 12
lymphoma, mantle-cell - therapy (12) 12
multiple myeloma - drug therapy (12) 12
non-hodgkins-lymphoma (12) 12
stem cell transplantation (12) 12
transplantation, autologous (12) 12
antineoplastic agents - therapeutic use (11) 11
care and treatment (11) 11
chronic lymphocytic-leukemia (11) 11
hematopoietic stem cell transplantation - methods (11) 11
immunochemotherapy (11) 11
lymphoma, mantle-cell - drug therapy (11) 11
multiple myeloma - metabolism (11) 11
neoplasm staging (11) 11
progression-free survival (11) 11
time factors (11) 11
versus-host-disease (11) 11
antineoplastic agents - pharmacology (10) 10
antineoplastic combined chemotherapy protocols - adverse effects (10) 10
combined modality therapy (10) 10
follicular lymphoma (10) 10
immune system diseases (10) 10
medicine & public health (10) 10
multiple myeloma - pathology (10) 10
non-hodgkin-lymphoma (10) 10
relapse (10) 10
research (10) 10
expression (9) 9
high-dose therapy (9) 9
human health and pathology (9) 9
kaplan-meier estimate (9) 9
remission induction (9) 9
transplantation conditioning - methods (9) 9
allogeneic stem cell transplantation (8) 8
clinical trials (8) 8
death (8) 8
dexamethasone (8) 8
drug therapy (8) 8
france (8) 8
gene expression regulation, neoplastic (8) 8
lymphoma, follicular - pathology (8) 8
lymphoma, mantle-cell - mortality (8) 8
multiple myeloma - genetics (8) 8
patients (8) 8
stem-cell transplantation (8) 8
animals (7) 7
antineoplastic combined chemotherapy protocols - administration & dosage (7) 7
autologous stem cell transplantation (7) 7
dexamethasone - administration & dosage (7) 7
drug administration schedule (7) 7
drug resistance, neoplasm - drug effects (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Leukemia, ISSN 0887-6924, 03/2016, Volume 30, Issue 3, pp. 761 - 764
INHIBITION | ONCOLOGY | MCL-1 | DEATH | LEUKEMIA | HEMATOLOGY | ABT-199 | ADDICTION | Recurrence | Antineoplastic Agents - chemical synthesis | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Myeloid Cell Leukemia Sequence 1 Protein - metabolism | bcl-X Protein - genetics | Male | Plasma Cells - pathology | Plasma Cells - drug effects | Proto-Oncogene Proteins c-bcl-2 - metabolism | Peptides - chemical synthesis | bcl-X Protein - antagonists & inhibitors | Aged, 80 and over | Biological Assay | Female | Plasma Cells - metabolism | Antineoplastic Agents - pharmacology | Bridged Bicyclo Compounds, Heterocyclic - chemical synthesis | Myeloid Cell Leukemia Sequence 1 Protein - antagonists & inhibitors | Aniline Compounds - pharmacology | Cytochromes c - secretion | Multiple Myeloma - diagnosis | Mitochondria - metabolism | Mitochondria - drug effects | Mitochondria - pathology | Multiple Myeloma - metabolism | Organ Specificity | Sulfonamides - pharmacology | Myeloid Cell Leukemia Sequence 1 Protein - genetics | Peptides - pharmacology | Sulfonamides - chemical synthesis | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | Multiple Myeloma - pathology | Cell Line, Tumor | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Aged | bcl-X Protein - metabolism | Proto-Oncogene Proteins c-bcl-2 - genetics | Aniline Compounds - chemical synthesis | Multiple Myeloma - genetics | Drug metabolism | Development and progression | Genetic aspects | Tumor proteins | Health aspects | Multiple myeloma | Life Sciences | Cancer | BCL-2 | BH3 profiling | BH3 mimetics | Multiple Myeloma | Apoptosis
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10036, pp. 2402 - 2411
Summary Background Short intensive chemotherapy is the standard of care for adult patients with Burkitt's leukaemia or lymphoma. Findings from single-arm... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | CODOX-M/IVAC | CLEAVED-CELL LYMPHOMA | ACUTE-LYMPHOBLASTIC-LEUKEMIA | MULTIAGENT CHEMOTHERAPY | ADOLESCENTS | PLUS RITUXIMAB | NON-HODGKIN-LYMPHOMA | SURVIVAL RATE | PEDIATRIC-ONCOLOGY-SOCIETY | CHILDREN | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Injections, Intravenous | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Patient Selection | Burkitt Lymphoma - pathology | Hydrocortisone - administration & dosage | Vincristine - administration & dosage | Adult | Female | France | Odds Ratio | Burkitt Lymphoma - drug therapy | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Drug Administration Schedule | Biomarkers, Tumor - analysis | Proportional Hazards Models | Treatment Outcome | Burkitt Lymphoma - diagnosis | Burkitt Lymphoma - chemistry | Cytarabine - administration & dosage | Rituximab - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Methotrexate - administration & dosage | Aged | Bone Marrow Neoplasms - drug therapy | Neoplasm Staging | Central Nervous System Neoplasms - drug therapy | Methylprednisolone - administration & dosage | Chemotherapy | Leukemia | Lymphomas | Adults | Epidemiology | Biometry | Cancer | Survival analysis | Biomedical research | Dehydrogenases | Medical prognosis | Clinical trials
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2017, Volume 377, Issue 13, pp. 1250 - 1260
Journal Article
Journal Article
The Lancet, ISSN 0140-6736, 02/2018, Volume 391, Issue 10121, pp. 659 - 667
Journal Article
Blood, ISSN 0006-4971, 10/2018, Volume 132, Issue 14, pp. 1486 - 1494
Obinutuzumab is a type II anti-CD20 monoclonal antibody that enhances antibody-dependent cellular cytotoxicity better than rituximab. Given promising results... 
TRIAL | RESPONSE CRITERIA | RITUXIMAB | NATURAL-KILLER-CELL | ANTIBODY | HEMATOLOGY | CYTOTOXICITY | GA101 | Life Sciences | Cancer | Clinical Trials and Observations
Journal Article
Journal Article
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2013, Volume 31, Issue 1, pp. 104 - 110
Journal Article
Journal Article